CLOV (US)


August 21, 2026

[HUM, ALHC, UNH, CVS, AGL, ASTH]: MA Tech Changes Rule Expectations: Stars Likely in Focus, Major Risk Adjustment Change Seem Less So

By Beth Steindecker

The pending Contract Year (CY) 2028 Technical and Policy Changes proposal for the Medicare Advantage (MA) insurers [HUM, ALHC, UNH, CVS, ELV, CNC, CLOV, MOH] and MA-exposed providers [AGL, ASTH] could be relatively more consequential…

Read More >>

June 1, 2026

CLOV Star Ratings Legal Win Creates System Uncertainty but Potentially Strengthens HUM Appeal

By Beth Steindecker

Last week’s federal court ruling in favor Clover Health (CLOV) against CMS injects fresh uncertainty into the Medicare Advantage (MA) Star Ratings and quality bonus payment framework [UNH, HUM, ELV, CVS, ALHC, CNC, MOH]. While…

Read More >>

October 14, 2025

[HUM] Stars Rating Litigation Likely Brings Chapter to Close

By Beth Steindecker

We think this morning’s court ruling against Humana (HUM) in its Medicare Advantage (MA) Stars litigation is likely the end of the road in its efforts to secure a higher score for its 2026 payment…

Read More >>

January 11, 2025

[HUM, UNH, CVS, ELV, ALHC] CY26 Medicare Advantage Rates: Likely Upswing in the Final

By Beth Steindecker

CMS’s Friday release of the CY26 Advance Notice (AN) for Medicare Advantage (MA) insurers [HUM, UNH, CVS, ELV, ALHC, CLOV, CNC] came in better than our net YoY benchmark expectations with a proposed net increase…

Read More >>